BRAF and non-small cell lung carcinoma: The combination of vemurafenib and everolimus (anti-mTOR) demonstrated promising activity in 20 patients with BRAF-mutant advanced cancers (1 NSCLC), including those previously treated with a BRAF inhibitor [97].